CD33 and acute myeloid leukemia: In a similar mode, the CD33/CD3 bispecific T cell engager AMV564 9, which has already been shown to have cytotoxic effect on CD33+AML cell lines, has been reported to effectively reduce the number of MDS-derived BM MDSCs ex vivo and improve the clonogenic capacity of MDS BMMCs [103].